Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.

Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, Rodallec A, Leoz M, Montes B, Schneider V, Plantier JC, Dina J, Pallier C, Mirand A, Roussel C, Signori-Schmuck A, Raymond S, Calvez V, Delaugerre C, Marcelin AG, Descamps D.

J Antimicrob Chemother. 2018 Jan 12. doi: 10.1093/jac/dkx511. [Epub ahead of print]

PMID:
29342281
2.

Impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen.

Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J; ANRS AC11 Resistance Study Group.

Clin Infect Dis. 2017 Dec 13. doi: 10.1093/cid/cix1070. [Epub ahead of print]

PMID:
29244143
3.

Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy.

Allavena C, Rodallec A, Leplat A, Hall N, Luco C, Le Guen L, Bernaud C, Bouchez S, André-Garnier E, Boutoille D, Ferré V, Raffi F.

J Virol Methods. 2018 Jan;251:106-110. doi: 10.1016/j.jviromet.2017.10.016. Epub 2017 Oct 16.

PMID:
29042218
4.

Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH).

Nordmann S, Vilotitch A, Roux P, Esterle L, Spire B, Marcellin F, Salmon-Ceron D, Dabis F, Chas J, Rey D, Wittkop L, Sogni P, Carrieri P; ANRS CO13 HEPAVIH Study Group.

J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12797. [Epub ahead of print]

PMID:
28984055
5.

Ageing with HIV: do comorbidities and polymedication drive treatment optimization?

Cuzin L, Katlama C, Cotte L, Pugliese P, Cheret A, Bernaud C, Rey D, Poizot-Martin I, Chirouze C, Bani-Sadr F, Cabié A; Dat'AIDS Study Group.

HIV Med. 2017 Jul;18(6):395-401. doi: 10.1111/hiv.12441. Epub 2016 Oct 7.

PMID:
28858437
6.

No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France.

Cuzin L, Yazdanpanah Y, Huleux T, Cotte L, Pugliese P, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Delpierre C; Dat'AIDS Study Group.

HIV Med. 2017 Aug 18. doi: 10.1111/hiv.12545. [Epub ahead of print]

PMID:
28834136
7.

An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.

Andre-Garnier E, Besse B, Rodallec A, Ribeyrol O, Ferre V, Luco C, Le Guen L, Bourgeois N, Gournay J, Billaud E, Raffi F, Coste-Burel M, Imbert-Marcille BM.

PLoS One. 2017 Jul 20;12(7):e0179562. doi: 10.1371/journal.pone.0179562. eCollection 2017.

8.

Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies.

Gantner P, Mélard A, Damond F, Delaugerre C, Dina J, Gueudin M, Maillard A, Sauné K, Rodallec A, Tuaillon E, Plantier JC, Rouzioux C, Avettand-Fenoel V; ANRS-AC11 Quantification Working Group.

J Med Virol. 2017 Nov;89(11):2047-2050. doi: 10.1002/jmv.24874. Epub 2017 Jul 6.

PMID:
28617961
9.

Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?

Pradat P, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat'AIDS study Group.

J Infect. 2017 Sep;75(3):234-241. doi: 10.1016/j.jinf.2017.05.008. Epub 2017 Jun 2.

PMID:
28579302
10.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.

Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D; Dat'AIDS study group.

HIV Med. 2017 Oct;18(9):704-708. doi: 10.1111/hiv.12506. Epub 2017 Apr 26. No abstract available.

PMID:
28444816
11.

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Nguyen TH, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F; JIKI study group.

PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.

12.

Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses.

Riou R, Bressollette-Bodin C, Boutoille D, Gagne K, Rodallec A, Lefebvre M, Raffi F, Senitzer D, Imbert-Marcille BM, Retière C.

J Virol. 2017 Feb 14;91(5). pii: e02245-16. doi: 10.1128/JVI.02245-16. Print 2017 Mar 1.

13.

Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.

Bernaud C, Khatchatourian L, Rodallec A, Hall N, Perre P, Morrier M, Pineau S, Jovelin T, André-Garnier E, Raffi F, Allavena C.

Infect Dis (Lond). 2016 Oct;48(10):754-9. doi: 10.1080/23744235.2016.1194528. Epub 2016 Jul 8.

PMID:
27389932
14.

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.

Lambert-Niclot S, Allavena C, Grude M, Flandre P, Sayon S, Andre E, Wirden M, Rodallec A, Jovelin T, Katlama C, Calvez V, Raffi F, Marcelin AG.

J Antimicrob Chemother. 2016 Aug;71(8):2248-51. doi: 10.1093/jac/dkw146. Epub 2016 May 26.

PMID:
27231280
15.

Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.

Flandre P, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Cuzin L; Dat'AIDS Study group.

HIV Med. 2016 May;17(5):380-4. doi: 10.1111/hiv.12306. Epub 2015 Aug 26.

PMID:
27093565
16.

Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.

Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabie A, Cheret A, Lahoulou R, Raffi F, Pugliese P; Dat’AIDS Study group.

Infect Dis (Lond). 2016;48(5):392-8. doi: 10.3109/23744235.2015.1133927. Epub 2016 Jan 13.

PMID:
26757613
17.

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach.

Cuzin L, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Flandre P; Dat'AIDS Study group.

Medicine (Baltimore). 2015 Sep;94(39):e1668. doi: 10.1097/MD.0000000000001668.

18.

Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.

Launay M, Dahan L, Duval M, Rodallec A, Milano G, Duluc M, Lacarelle B, Ciccolini J, Seitz JF.

Br J Clin Pharmacol. 2016 Jan;81(1):124-30. doi: 10.1111/bcp.12790. Epub 2015 Nov 28.

19.

Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy.

Cuzin L, Pugliese P, Sauné K, Allavena C, Ghosn J, Cottalorda J, Rodallec A, Chaix ML, Fafi-Kremer S, Soulié C, Ouka M, Charpentier C, Bocket L, Mirand A, Guiguet M; Dat’AIDS study group.

AIDS. 2015 Aug 24;29(13):1665-71. doi: 10.1097/QAD.0000000000000723.

PMID:
26372277
20.

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671.

Supplemental Content

Loading ...
Support Center